The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I lost my dad to cancer and the fact a drug is out there that cod save lives is being ignored because of nonsense......love to see Sierra fold ........
Given srra unreliability on drugs they have partnered previously. It is feasible that a large partner would rather deal with crt direct rather than the unreliable srra. Its feasible there is a deal ready to go once handed back (would explain a lot). But again pure speculation on my part.
My guess is early november. No facts. But the agreement with srra was amended on 9th november last year. And i assume they were given a year to put up or give back. An assumption but reasonable
Hi thoth. How long you think that cruk will give sierea to move forward on chk1? Surely tome costs lifes. We know as combo it kicks ass.....a disgrace fir patients being not given a chance for good outcome.
https://clincancerres.aacrjournals.org/content/23/12/3097
And here. As cct245737 (name before licence to sierra). We are the only chk1 still in development.
Mentioned here
https://pubmed.ncbi.nlm.nih.gov/30024813/
Todays times.
I’m sure Olaparib/Lynparza was linked to sra737 a while back Citizen do you recollect?
https://www.thetimes.co.uk/article/success-of-astrazeneca-drug-raises-hopes-for-prostate-cancer-patients-hpxf9j2wv
Mid year starts with Q3, and we are still in Q3. BOD may have had results weeks ago, but they do not have to tell us immediately. Cannot be far away though.
Desa, could it be Dr Reader has pulled a master stroke and the secret patent is linked to all respiratory illnesses.
Remember they are investigating bacterial pneumonia- so this delay may well be linked. If so, it would be enormous and would explain the delay.
This was from the 01 July covid research update-
'A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model'.
Doesn't say it failed just inconclusive and the disease model was likely provided by UKRI. Now if the HNWI's have invested to further investigate this and for arguments sake it is as Thoth thinks wellcome they will have via WHO alternative models to utilise and it could mean game on.
Get the old ticker working doesn't it. Oh the suspense of the secret patent revealing.
Many happy returns chaps can only be a positive as if any bad news was coming they would released it by now.
Also this from the Q&A….
“Q9: In respect of cytokine activation in acute critical illness, this occurs in other conditions apart from Covid 19. Is there any evidence that your therapy may ameliorate this and prevent ARDS in other conditions? Are you able to give any more detail on the activities completed on the COVID tests? Can you tell us any more about the observations seen in human lung cells in the 1801 preclin work and is there read across here beyond Covid and indeed beyond lung conditions?
There is evidence in the literature that TYK2 inhibition may ameliorate the cytokine storm in other viral infections, such as influenza, and we are also undertaking some early preclinical studies with SDC-1801 in this area.
We will provide further details when the project is completed and the results are analysed, expected mid-year.“
Mid year ? We are now entering late year.
The FOI request should have a response this week, I wonder if the UKRI will let a cat out the bag before any news is released. They say the response will be by 1st Oct, the last response was about 7 days before the deadline. Tick tock.
A very astute comment Mayhem 55.
Also bare in mind Tim Mitchells ' transformational deal' circa 2012. He will not go through that again.
When confirmed ( no longer subject to), up and coming anticipated positive news is released then, that will then involve formal offers to which we will have to be notified.
Regards
Oh yes they are in talks for sure ... Hence the silence .. as you mention DG takes for ever and the valuation of IP and patents not as simple as some may believe ... They have the mother lode OK ... But are waiting for the machinery to extract it ... So to speak ... All we need to do is wait patiently and watch for the "ore trucks" to start rolling ..
It has been some time now since we had a investor session. It could be they have nothing to say or more likely they don’t / can’t face questions that may compromise any deals that are being discussed. I have little understanding of the science but have board room experience of large buy in / outs, so it looks to me as though we are deep in discussions with potential suitors. The due diligence takes ages and it is also likely tied into the patents and data timelines. Given we have a patent due shortly, I am assuming this will be the catalyst for a company update.